Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neeraj Narula

Showing results (151-160 of 204) with videos related to

Pageof 21
Sort By:
Gut|March 26, 2021
Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD)Neeraj Narula, Emily C L Wong, Jean-Frederic Colombel, et al.
Digestive Diseases and Sciences|March 4, 2022
Effectiveness of Tofacitinib for Hospitalized Patients with Acute Severe Ulcerative Colitis: Case SeriesYasi Xiao, Nicolas Benoit, Rocio Sedano, et al.
Crohn'S & Colitis 360|March 17, 2025
Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management (The TRIUMPH Study)Neeraj Narula, Cara Pray, Hasan Hamam, et al.
Journal of Gastroenterology and Hepatology|February 22, 2022
Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancyBadar Hasan, Kanwarpreet Singh Tandon, Rafael Miret, et al.
Journal of the Canadian Association of Gastroenterology|July 12, 2019
Impact of Adalimumab Patient Support Program's Care Coach Calls on Clinical Outcomes in Patients with Crohn's Disease in Canada: An Observational Retrospective Cohort StudyNeeraj Narula, Brad Millson, Katia Charland, et al.
Eclinicalmedicine|December 11, 2024
Corrigendum to "Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trials" volume 72, 102621Sudheer K Vuyyuru, Christopher Ma, Tran M Nguyen, et al.
Journal of Crohn'S & Colitis|June 13, 2024
Adaptive Steroid Tapering Impedes Corticosteroid-free Remissions Compared with Forced Tapering in Clinical Trials of Ulcerative ColitisNeeraj Narula, Hasan Hamam, Jasmine Liu, et al.
Eclinicalmedicine|May 10, 2024
Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trialsSudheer K Vuyyuru, Christopher Ma, Tran M Nguyen, et al.
Journal of Clinical Gastroenterology|November 10, 2021
Week 2 Adalimumab Levels Predict Short-term Clinical Remission in Patients With Inflammatory Bowel DiseaseElisa Buffone, Shaan Gupta, Bashaar Al Ibrahim, et al.
Gastro Hep Advances|December 9, 2025
Drug Discontinuation and Persistent Symptoms Among Initiators of Bio-Originator and Biosimilar anti-Tumor Necrosis Factor Drugs in Inflammatory Bowel Disease: Real-World Contemporary Data From the CAnadian Network for Advanced Interdisciplinary Methods/CIRC RegistryBanke Oketola, Sasha Bernatsky, Luck Lukusa, et al.
Pageof 21

Showing results (151-160 of 204) with videos related to

Sort By:
Pageof 21
Gut|March 26, 2021
Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD)Neeraj Narula, Emily C L Wong, Jean-Frederic Colombel, et al.
Digestive Diseases and Sciences|March 4, 2022
Effectiveness of Tofacitinib for Hospitalized Patients with Acute Severe Ulcerative Colitis: Case SeriesYasi Xiao, Nicolas Benoit, Rocio Sedano, et al.
Crohn'S & Colitis 360|March 17, 2025
Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management (The TRIUMPH Study)Neeraj Narula, Cara Pray, Hasan Hamam, et al.
Journal of Gastroenterology and Hepatology|February 22, 2022
Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancyBadar Hasan, Kanwarpreet Singh Tandon, Rafael Miret, et al.
Journal of the Canadian Association of Gastroenterology|July 12, 2019
Impact of Adalimumab Patient Support Program's Care Coach Calls on Clinical Outcomes in Patients with Crohn's Disease in Canada: An Observational Retrospective Cohort StudyNeeraj Narula, Brad Millson, Katia Charland, et al.
Eclinicalmedicine|December 11, 2024
Corrigendum to "Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trials" volume 72, 102621Sudheer K Vuyyuru, Christopher Ma, Tran M Nguyen, et al.
Journal of Crohn'S & Colitis|June 13, 2024
Adaptive Steroid Tapering Impedes Corticosteroid-free Remissions Compared with Forced Tapering in Clinical Trials of Ulcerative ColitisNeeraj Narula, Hasan Hamam, Jasmine Liu, et al.
Eclinicalmedicine|May 10, 2024
Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trialsSudheer K Vuyyuru, Christopher Ma, Tran M Nguyen, et al.
Journal of Clinical Gastroenterology|November 10, 2021
Week 2 Adalimumab Levels Predict Short-term Clinical Remission in Patients With Inflammatory Bowel DiseaseElisa Buffone, Shaan Gupta, Bashaar Al Ibrahim, et al.
Gastro Hep Advances|December 9, 2025
Drug Discontinuation and Persistent Symptoms Among Initiators of Bio-Originator and Biosimilar anti-Tumor Necrosis Factor Drugs in Inflammatory Bowel Disease: Real-World Contemporary Data From the CAnadian Network for Advanced Interdisciplinary Methods/CIRC RegistryBanke Oketola, Sasha Bernatsky, Luck Lukusa, et al.
Pageof 21